Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesothelioma

1 Apr 2025

Abstract excerpt

INTRODUCTION: Peritoneal, pericardial and pleural mesothelioma (PeM/PcM/PM) are rare and aggressive diseases with limited survival. Molecularly guided therapy is currently not part of standard care. METHODS: This study integrates molecular and clinical data from 51 patients (among them 28 PM, one PcM, 21 PeM and one synchronous PeM/PM) enrolled in the National Center for Tumor Diseases and the German Cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Research and Treatments
Share to Genetic factors in colorectal cancer
Share to Occupational and environmental lung diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40174508
DOI: 10.1016/j.esmoop.2025.104532

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesotheliomaPMID 40174508Read ↗

Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies.Semantic proximity Read ↗

Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice.Semantic proximity Read ↗

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesotheliomaSemantic proximity Read ↗

BAP1 Loss Predicts Therapeutic Vulnerability in Malignant Peritoneal MesotheliomaSemantic proximity Read ↗

Genomic Landscape of Malignant Mesotheliomas.Semantic proximity Read ↗

Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma.Semantic proximity Read ↗

Personalized Oncogenomics: Clinical Experience with Malignant Peritoneal Mesothelioma Using Whole Genome SequencingSemantic proximity Read ↗

Isolated BAP1 Genomic Alteration in Malignant Pleural Mesothelioma Predicts Distinct Immunogenicity with Implications for Immunotherapeutic ResponseSemantic proximity Read ↗

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.Semantic proximity Read ↗

Transcriptomics based prediction of survival and response to therapy in malignant mesotheliomaSemantic proximity Read ↗

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.Semantic proximity Read ↗

Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesotheliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.